Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial - Leiter, Lawrence A.; Teoh, Hwee; Kallend, David; Wright, R. Scott; Landmesser, Ulf; Wijngaard, Peter L.J.; Kastelein, John J.P.; Ray, Kausik K. (Diabetes care, 2019)
Keywords: Apolipoprotein B; Apolipoproteins B - blood; Arteriosclerosis; Atherosclerosis; Atherosclerosis - blood; Atherosclerosis - drug therapy; Cardiovascular disease; Cardiovascular diseases; Cholesterol; Cholesterol, HDL - blood; Cholesterol, LDL - blood; Clinical trials; Diabetes; Diabetes mellitus; Diabetes Mellitus - blood; Diabetes Mellitus - drug therapy; Dose-Response Relationship, Drug; Dyslipidemia; Dyslipidemias - blood; Dyslipidemias - drug therapy; Evidence-based medicine; Female; Health risks; High density lipoprotein; Humans; Kexin; Lipids; Low density lipoprotein; Male; Metabolic disorders; Middle Aged; Proprotein Convertase 9 - blood; Research design; Risk Factors; RNA, Small Interfering - pharmacology; siRNA; Subtilisin